1 option
Engineering mRNA Lipid Nanoparticles to Overcome Barriers to T Cell Cancer Immunotherapy Ann Metzloff
- Format:
- Book
- Thesis/Dissertation
- Author/Creator:
- Metzloff, Ann, author.
- Language:
- English
- Subjects (All):
- 0202.
- 0982.
- 0307.
- 0572.
- Local Subjects:
- 0202.
- 0982.
- 0307.
- 0572.
- Genre:
- Academic theses
- Physical Description:
- 1 electronic resource (165 pages)
- Contained In:
- Dissertations Abstracts International 88-03B
- Place of Publication:
- Ann Arbor : ProQuest Dissertations and Theses, 2026
- Language Note:
- English
- Summary:
- Adoptive cell therapy (ACT), which includes T cell receptor (TCR), chimeric antigen receptor (CAR), and tumor infiltrating lymphocyte (TIL) therapy is a promising form of immunotherapy for the treatment of cancer. However, each class faces its own specific barriers, including costly and time-consuming production workflows, immunosuppressive tumor microenvironments, and antigenic heterogeneity and loss. Lipid nanoparticles (LNPs) are the leading non-viral delivery platform for nucleic acid therapies. Thus, in this dissertation, mRNA LNPs were developed to overcome specific barriers faced by adoptive cell therapies. In the first half of the dissertation, T cell activating LNPs (aLNPs) were designed to address challenges in current ex vivo CAR T cell manufacturing, a slow, stepwise, and expensive process which requires T cell activating beads. aLNPs were designed to have surface-conjugated CD3 and CD28 antibodies thus combining the antigen presenting cell mimetic nature of commonly used T cell activating beads with the mRNA transfecting capabilities of LNPs. aLNPs were shown to facilitate one-step activation and transfection of primary human T cells with CAR mRNA without requiring activating beads. The resulting mRNA CAR T cells were shown to reduce tumor burden in a murine xenograft model of leukemia, indicating aLNPs as a promising platform for the rapid production of mRNA CAR T cells. In the second half of the dissertation, mRNA LNPs containing a novel membrane-bound IL-12 and a mesothelin T cell engager were engineered to combat immunosuppressive tumor microenvironments and antigen heterogeneity and loss, challenges which are faced broadly by ACTs for the treatment of solid tumors. Intratumoral administration of the dual LNP therapy resulted in robust improvements in TCR T cell therapy efficacy in a murine xenograft model of human lung adenocarcinoma. While delivery of either mRNA construct alone improved TCR T cell therapy efficacy, combined delivery of both constructs resulted in an additive improvement in efficacy. In all, this dissertation lays the foundation for broad applications of mRNA LNP technology to enhance T cell cancer immunotherapy
- Notes:
- Source: Dissertations Abstracts International, Volume: 88-03, Section: B.
- Advisors: Mitchell, Michael Committee members: Momin, Noor; Sheppard, Neil; Tsourkas, Andrew
- Ph.D. University of Pennsylvania 2026
- Includes bibliographical references
- Local Notes:
- School code: 0175
- ISBN:
- 9798189294099
- Access Restriction:
- Restricted for use by site license
The Penn Libraries is committed to describing library materials using current, accurate, and responsible language. If you discover outdated or inaccurate language, please fill out this feedback form to report it and suggest alternative language.